VYZULTATM(latanoprostene bunod ophthalmic solution), 0.024%
VYZULTA Rx
Generic Name and Formulations:
Latanoprostene bunod 0.024%; oph soln; contains benzalkonium chloride.
Company:
Valeant Pharmaceuticals, Inc
Indications for VYZULTA:
Open-angle glaucoma. Ocular hypertension.
Adult:
>16yrs: 1 drop once daily in the PM.
Children:
≤16yrs: not recommended.
Warnings/Precautions:
Do not exceed recommended dose (may reduce efficacy). History of ocular inflammation: not recommended if active inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Bacterial keratitis may occur (due to multiple-dose containers). Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
Interactions:
Allow at least 5mins between application of other topical oph agents.
Pharmacological Class:
Prostaglandin analogue.
Adverse Reactions:
Conjunctival hyperemia, eye irritation, eye pain, instillation site pain; increased ocular pigmentation (eg, iris [may be permanent], eyelid, eyelashes), other eyelash/lid changes, macular edema (including cystoid macular edema).
Generic Availability:
NO
How Supplied:
Soln—5mL |
